Elevated expression of Rab25 was significantly associated with shorter survival time of patients with bladder cancer [20], advanced non-small cell lung cancer [19], ovarian cancer [12], breast cancer [12, 49], clear cell renal cell carcinoma [15] and prostate cancer [22]. Here, RAB25 is linked to non-small cell lung carcinoma.